Economic cost for implementation of the U.S. Food and Drug Administration's Code of Federal Regulations Title 21, Part 1271 in an egg donor program

Fertility and Sterility

Volumn 90, Issue 3, 2008, Pages 537-545

  Baker, Valerie L ^a,b   Gvakharia, Marina O ^a   Rone, Heather M ^a   Manalad, James R ^a   Adamson, G David ^a,b  

^a Fertility Physicians of Northern California   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Egg donation; regulations; screening

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DONOR SELECTION; FERTILIZATION IN VITRO; FOOD AND DRUG ADMINISTRATION; HEALTH PROGRAM; HUMAN; LABORATORY TEST; OOCYTE DONATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRIVATE PRACTICE; QUESTIONNAIRE; SOCIOECONOMICS; STRUCTURED INTERVIEW;

CALIFORNIA; COMMUNICABLE DISEASE CONTROL; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE COSTS; HUMANS; TISSUE DONORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 51549114642     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.06.100     Document Type: Article

References (10)

1. American Society for Reproductive Medicine. 2002 guidelines for gamete and embryo donation: a practice committee report: guidelines and minimum standards. Fertil Steril 82 Suppl 1 (2004) S8
2. The Practice Committee of the American Society for Reproductive Medicine and the Practice Committee of the Society for Assisted Reproductive Technology. 2006 Guidelines for gamete and embryo donation. Fertil Steril 86 Suppl 5 (2006) S38-S50
3. Center for Devices and Radiological Health (CDRH), U.S. Food and Drug Administration. Title 21-Food and Drugs. Chapter I: Food and Drug Administration, Department of Health and Human Services. Subchapter L: Regulations under Certain Other Acts Administered by the Food and Drug Administration. Part 1271: Human Cells, Tissues, and Cellular and Tissue-Based Products. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CF RPart=1271.
4. Center for Devices and Radiological Health (CDRH), U.S. Food and Drug Administration. Electronic Human Cell and Tissue Establishment Registration (eHCTERS). Updated July 5, 2007. Available at: http://www.fda.gov/cber/tissue/tisreg.htm.
5. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. 2003 Assisted Reproductive Technology (ART) Report: Fertility Clinic Report by State: Clinic Map. Available at: http://apps.nccd.cdc.gov/ART2003/clinics03.asp.
6. Neidinger J, for the Office of Cellular, Tissue, and Gene Therapies Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. FDA Update: Regulation of Reproductive Human Cells, Tissues, and Cellular and Tissue Based Products (HCT/Ps). October 2006. Available at: http://www.fda.gov/cber/tissue/asrm102206jn.pdf.
7. Lesourd F., Izopet J., Mervan C., Payen J.L., Sandres K., Monrozies X., and Parinaud J. Transmissions of hepatitis C virus during the ancillary procedures for assisted conception. Hum Reprod 15 (2000) 1083-1085
8. Sauer M.V. American physicians remain slow to embrace the reproductive needs of human immunodeficiency virus-infected patients. Fertil Steril 85 (2006) 295-297
9. Lyerly A.D., and Anderson J. Human immunodeficiency virus and assisted reproduction: reconsidering evidence, reframing ethics. Fertil Steril 75 (2001) 843-858
10. Daar J.F. Regulating reproductive technologies: panacea or paper tiger?. Houst Law Rev 34 (1997) 609-664